Key result
Nifedipine GITS was as effective as co-amilozide in preventing cardiovascular events in hypertensive diabetics (8.3% vs 8.4%; RR 0.99; 95% CI 0.69-1.42; P=1.00).
Why the study?
Does nifedipine GITS reduce cardiovascular events compared to co-amilozide in hypertensive patients with and without diabetes?
RCT (n=6,321)
Yes
Does nifedipine GITS reduce cardiovascular events compared to co-amilozide in hypertensive patients with and without diabetes?
Relative Risk: 0.99 (95% CI 0.69–1.42)
Absolute Event Rate: 8.3% vs 8.4%
p-value: p=1.00
Nifedipine GITS is as effective as diuretic therapy for primary cardiovascular prevention in hypertensive diabetics, while offering benefits in reducing secondary events and new-onset diabetes.
No takes yet. Share an insight, caveat, or question.
Supports nifedipine GITS as alternative to diuretics for CV prevention in hypertensive diabetics; confirms equivalence in this RCT subgroup.
Mancia et al. (2003) conducted an RCT in Hypertension (n=6,321). Nifedipine GITS vs. Co-amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily was evaluated on Composite of cardiovascular death, myocardial infarction, heart failure, and stroke (RR 0.99, 95% CI 0.69-1.42, p=1.00). Nifedipine GITS was as effective as co-amilozide in preventing cardiovascular events in hypertensive diabetics (8.3% vs 8.4%; RR 0.99; 95% CI 0.69-1.42; P=1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: